Sofya Tokman

Sofya Tokman

Auto-generated profile, based on publicly available information

Sofya Tokman

Division of Transplant Pulmonology Norton Thoracic Institute Dignity Health St. Joseph's Hospital and Medical Center Phoenix Arizona USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
STSofya Tokman
Sofya Tokman
JSJonathan P. Singer
Jonathan P. Singer
MDMegan S. Devine
Megan S. Devine
GWGlen P. Westall
Glen P. Westall
JAJohn-David Aubert
John-David Aubert
SHSteven R. Hays
Steven R. Hays

28 September 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
KGKellie J. Goodlet
Kellie J. Goodlet
STSofya Tokman
Sofya Tokman
ANAasya Nasar
Aasya Nasar
LCLauren Cherrier
Lauren Cherrier
RWRajat Walia
Rajat Walia
MNMichael D. Nailor
Michael D. Nailor

14 May 2024 in Transplant Infectious Disease
Verified
Journal Article
Closed access
SMSydni Martinez
Sydni Martinez
DSDevika Sindu
Devika Sindu
MNMichael D. Nailor
Michael D. Nailor
LCLauren Cherrier
Lauren Cherrier
STSofya Tokman
Sofya Tokman
KGKellie J. Goodlet
Kellie J. Goodlet

30 September 2020 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
KGKellie J. Goodlet
Kellie J. Goodlet
SBSandhya Bansal
Sandhya Bansal
AAAshwini Arjuna
Ashwini Arjuna
MNMichael D. Nailor
Michael D. Nailor
BBBhuvin Buddhdev
Bhuvin Buddhdev
STSofya Tokman
Sofya Tokman
Exosomes isolated from plasma of lung transplant recipients with allograft injury contain donor‐derived lung self‐antigens (collagen V and Kα1 tubulin) and human leukocyte antigen (HLA) molecules. We present a case of a 76‐year‐old, female lung transplant recipient treated for acute cellular rejection with methylprednisolone and anti‐thymocyte globulin, who subsequently contracted SARS‐CoV‐2 and developed a sharp increase in the mean fluorescent intensity of anti‐HLA antibodies. Analysis of circulating exosomes during rejection, but before SARS‐CoV‐2 infection, revealed the presence of lung self‐antigens and HLA class II molecules. After the patient contracted SARS‐CoV‐2, exosomes with the SARS‐CoV‐2 spike protein were also found. After resolution of infectious symptoms, exosomes with SARS‐CoV‐2 spike protein were no longer detected; however, exosomes with lung self‐antigens and HLA class II molecules persisted, which coincided with a progressive decline in spirometric flows, suggesting chronic lung allograft dysfunction. We propose that the analysis of circulating exosomes may be used to detect allograft injury mediated by both rejection and infection. Furthermore, the detection of exosomes containing viral proteins may be helpful in identifying allograft injury driven by viral pathogens.

1 January 2019 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
KGKellie J. Goodlet
Kellie J. Goodlet
MNMichael D. Nailor
Michael D. Nailor
AOAshraf Omar
Ashraf Omar
JHJasmine L. Huang
Jasmine L. Huang
JLJohn J. LiPuma
John J. LiPuma
STSofya Tokman
Sofya Tokman

12 May 2023 in Transplantation Direct
Verified
Journal Article
Open access
DSDevika Sindu
Devika Sindu
DRDeepika Razia
Deepika Razia
KGKatherine Rn Grief
Katherine Rn Grief
LCLauren Cherrier
Lauren Cherrier
AOAshraf Omar
Ashraf Omar
STSofya Tokman
Sofya Tokman
Background.: Lung transplant recipients (LTRs) have an increased risk of COVID-19–related morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal antibody combination granted Emergency Use Authorization approval by the US Food and Drug Administration for COVID-19 pre-exposure prophylaxis (PrEP) in immunocompromised patients. We sought to determine whether tix-cil 300–300 mg reduced the incidence and disease severity of severe acute respiratory syndrome coronavirus 2 infection in LTRs during the Omicron wave. Methods.: We performed a retrospective, single-center cohort study of LTRs who had received a COVID-19 diagnosis between December 2021 and August 2022. We compared baseline characteristics and clinical outcomes after COVID-19 between LTRs who received tix-cil PrEP and those who did not. We then conducted propensity-score matching based on baseline characteristics and therapeutic interventions and compared clinical outcomes between the 2 groups. Results.: Of 203 LTRs who received tix-cil PrEP and 343 who did not, 24 (11.8%) and 57 (16.6%), respectively, developed symptomatic COVID-19 (hazard ratio [HR], 0.669; 95% confidence interval [CI], 0.415-1.079; P = 0.099). The hospitalization rate of LTRs with COVID-19 during the Omicron wave trended lower in the tix-cil group than in the non–tix-cil group (20.8% versus 43.1%; HR, 0.430; 95% CI, 0.165-1.118; P = 0.083). In propensity-matched analyses, 17 LTRs who received tix-cil and 17 LTRs who did not had similar rates of hospitalization (HR, 0.468; 95% CI, 0.156-1.402; P = 0.175), intensive care unit admission (HR, 3.096; 95% CI, 0.322-29.771; P = 0.328), mechanical ventilation (HR, 1.958; 95% CI, 0.177-21.596; P = 0.583), and survival (HR, 1.015; 95% CI, 0.143-7.209; P = 0.988). COVID-19–related mortality was high in both propensity-score–matched groups (11.8%). Conclusions.: Breakthrough COVID-19 was common among LTRs despite tix-cil PrEP, possibly due to reduced efficacy of monoclonal antibodies against the Omicron variant. Tix-cil PrEP may reduce the incidence of COVID-19 in LTRs, but it did not reduce disease severity during the Omicron wave.